Royal Bank Of Canada Delcath Systems, Inc. Transaction History

Royal Bank Of Canada

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$4.47 - $8.37 $14,809 - $27,729	-3,313 Reduced 94.66%	187 $1,000
Q1 2024 Nov 05, 2024	BUY	$3.72 - $5.09 $12,324 - $16,863	3,313 Added 1771.66%	3,500 $16,000
Q1 2024 May 15, 2024	BUY	$3.72 - $5.09 $12,774 - $17,479	3,434 Added 5203.03%	3,500 $16,000
Q4 2023 Feb 14, 2024	SELL	$2.25 - $4.17 $2,124 - $3,936	-944 Reduced 93.47%	66 $0
Q3 2023 Nov 14, 2023	BUY	$3.12 - $5.85 $2,873 - $5,387	921 Added 1034.83%	1,010 $4,000
Q2 2023 Aug 14, 2023	BUY	$5.38 - $7.96 $478 - $708	89 New	89 $0
Q2 2022 Aug 15, 2022	SELL	$3.62 - $6.55 $5,430 - $9,825	-1,500 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$7.2 - $11.72 $10,800 - $17,580	1,500 New	1,500 $12,000

7.52M

198K

41.7K

Ticker DCTH
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 8,597,680
Market Cap $132M
Description
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling syste...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.